# OmniAb Inc. (OABI) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $4.33, market value $630 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). OmniAb Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 16.4×**. Each dollar of revenue is priced at 16.4×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.4×**. The shares trade at 2.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -2.9%** (5-yr avg -7.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -125.8%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -347.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: -24.3%**. Return on equity is negative because earnings are negative.
- **Return on assets: -14.7%**. Each dollar of assets produces -14.7% of profit.

## Growth
- **Revenue growth (1 yr): -29.3%** (3-yr -31.9%/yr). Revenue fell 29.3% over the last year.
- **EPS growth (1 yr): 6.6%**. Earnings per share rose 6.6%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 4.02** (quick 4.02). Current assets cover the next year's liabilities 4.02 times.
- **Altman Z-score: 11.89**. A Z-score of 11.89 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. OmniAb Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover OmniAb Inc.; the consensus is strong_buy, with an average price target of $8.40 (+94% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 170.6%** (YTD 134.1%, 3-mo 74.6%). The shares are up 170.6% over twelve months including dividends.
- **From 52-week high: -20.3%** (233.1% above the low). Trading 20% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 1.42** (volatility 75%). Beta of 1.42 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=OABI · Page: https://foliofundamentals.com/stocks/oabi

Not investment advice.